GeneDx (WGS) Q4 2025 earnings review
Record Revenue Ramp, But Heavy Investments Squeeze Profits
GeneDx delivered an exceptional top-line quarter, with total revenue hitting a record $121.0 million and core Exome/Genome volume growing an accelerating 34% YoY. The company is successfully executing its 'land grab' strategy in the rare disease market. However, this growth came at a steep cost. Adjusted operating expenses jumped to 68% of revenue, crushing Adjusted Net Income down to $4.4 million from $17.5 million a year ago. Management is deliberately trading near-term profitability for long-term market share in general pediatrics and the NICU. FY26 guidance projects robust 33-35% core growth, confirming that the aggressive reinvestment cycle will continue.
🐂 Bull Case
Exome and genome volumes are accelerating, reaching 27,761 tests in Q4. FY26 guidance calls for another 33-35% growth, indicating immense unmet demand and strong market capture.
Despite rapid volume scaling, Adjusted Gross Margins remained stable at 71%, proving the company's lab automation and AI interpretation tools can handle scale efficiently.
🐻 Bear Case
Adjusted Net Income collapsed 75% YoY to $4.4 million. The company is entering a heavy investment cycle (sales force expansion, brand marketing) that will limit bottom-line expansion in FY26.
Hereditary cancer revenue dropped to just $0.2 million in Q4. While expected, it forces the Exome/Genome segment to carry 100% of the company's growth burden.
⚖️ Verdict: ⚪
Cautiously Bullish. The top-line momentum is undeniable and the TAM expansion is real. However, investors must be prepared to stomach flat or compressed near-term earnings as management aggressively funds its sales force expansion into general pediatrics.
Key Themes
Core Exome & Genome Growth Accelerating
The foundation of GeneDx is its whole exome and genome testing, which is accelerating. Volume grew 34.3% YoY in Q4 (up from 33% in Q3 and 28% in Q2). Revenue for this segment hit $104.0 million, representing 86% of total company revenue. This proves that specialists continue to abandon outdated panel tests in favor of comprehensive sequencing.
Operating Expense Surge Compresses Profits
A major concern emerged in Q4: Adjusted total operating expenses spiked to $81.8 million, representing 68% of revenue (up from 61% in Q3 and 52% in 24Q4). Management previously flagged this as a deliberate reinvestment cycle to hire sales reps for the general pediatrics market, but the immediate impact was a decelerating Adjusted Net Income, which fell to just $4.4 million. The narrative contradicts the prior 'margin expansion' story.
Favorable Macro Payer Landscape
The macroeconomic environment for reimbursement is stable and improving. In 2025, GeneDx secured Medicaid coverage in 8 new states, bringing the total to 38 states for pediatric outpatient settings. Additionally, 17 states now cover rapid genome sequencing in the NICU. This broad payer support establishes a reliable floor for Average Selling Prices (ASP).
GeneDx Infinity & AI Data Moat
The company's competitive advantage lies in its proprietary data. GeneDx Infinity now holds over 1 million exomes and genomes and 8 million phenotypic data points. This massive dataset feeds their newly launched 'Multiscore' AI decision support tool, enabling faster interpretation, driving gross margins to 71%, and creating a barrier to entry that smaller labs cannot replicate.
Execution Risk in General Pediatrics
GeneDx is targeting 25,000 general pediatricians following new American Academy of Pediatrics (AAP) guidelines. However, selling to non-specialists requires significantly more education, workflow hand-holding, and a larger sales force. This transition carries high execution risk. If general pediatricians are slow to adopt the 'One-Minute Order' process, the heavy OpEx investments made in Q4 will fail to generate sufficient ROI.
Legacy Segments Practically Extinct
Hereditary cancer testing revenue decelerated to a mere $0.2 million in Q4, down from $2.8 million a year ago. 'Other panels' revenue remains stagnant at $13.1 million. While management intentionally pivoted away from these lower-margin areas, their total collapse means 100% of future company growth must be generated by the Exome/Genome segment.
Other KPIs
Stable. Gross margins remained incredibly consistent at 71% in Q4 (matching Q3 and up from 70% in 24Q4). This highlights excellent cost control in the laboratory and successful revenue cycle management, offsetting the massive spike in below-the-line operating expenses.
Accelerating. The balance sheet is fortress-like, growing from $156.1 million in Q3. Q4 operations generated $5.1 million in positive cash flow, and the company bolstered its position by raising $21.1 million via an ATM stock offering, providing ample runway for its 2026 expansion plans.
Guidance
Accelerating. The $547.5 million midpoint implies an impressive 28% year-over-year growth compared to FY25's $427.5 million. This reflects deep confidence that the recent investments in the sales force will translate directly into top-line acceleration.
Stable. This matches the 34.3% growth achieved in 25Q4 and the 30.5% growth for the full year 2025. It shows management expects the current aggressive adoption curve among pediatric neurologists and the NICU to maintain its momentum without slowing down.
Stable. A conservative baseline that aligns with the 71% achieved for the full year 2025. It suggests management does not foresee significant pricing pressure or reimbursement degradation as they expand into new indications.
Decelerating implicitly. Management promises to stay 'positive', but the lack of a specific dollar range—combined with Q4's sharp drop to $4.4M—suggests earnings will hover near breakeven as they aggressively funnel gross profits back into sales and marketing.
Key Questions
Operating Expense Trajectory
Adjusted OpEx spiked to 68% of revenue in Q4. Is this the new run-rate baseline for FY26 as you build out the general pediatrics sales team, or was there a one-time concentration of hiring and marketing spend in the fourth quarter?
General Pediatrics Adoption Metrics
With the AAP guidelines now in place, what specific early leading indicators (e.g., pilot program uptake, 'One-Minute Order' utilization) are you tracking to ensure the 18-24 month adoption timeline for general pediatricians remains on track?
Reimbursement Rates in New Markets
As you aggressively push into non-specialist channels and the NICU, are you modeling any degradation in Average Selling Price (ASP) or higher initial denial rates compared to your core geneticist user base?